Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
SymBio Pharmaceuticals clinical trials
The registry lists 25 studies whose lead sponsor is SymBio Pharmaceuticals. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the SymBio Pharmaceuticals studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to SymBio Pharmaceuticals.
- SymBio Pharmaceuticals25 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 25 of 25.
- A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCTRecruitingNCT07387367Phase 3
- A Phase 2a Study of IV BCV in Subjects With Adenovirus InfectionCompletedNCT04706923Phase 2
- A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell LymphomaSuspendedNCT06761677Phase 1/2
- Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney TransplantationTerminatedNCT05511779Phase 2
- Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat LymphomaCompletedNCT03900377Phase 1/2
- Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCLCompletedNCT04354402
- Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell LymphomaCompletedNCT03372837Phase 3
- Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)CompletedNCT01700335Phase 1
- Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)CompletedNCT02014051Phase 1
- Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative PainTerminatedNCT03005899Phase 3
- Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic SyndromeWithdrawnNCT02783547Phase 1
- Study of SyB C-1101 in Patients With Myelodysplastic SyndromeCompletedNCT03495167Phase 1
- A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's LymphomaCompletedNCT00794638Phase 1
- Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy SubjectsCompletedNCT04542252Phase 1
- SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid TumorsCompletedNCT03604679Phase 1
- A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT00389051Phase 1
- Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension StudyCompletedNCT02000154Phase 1
- Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension StudyCompletedNCT02002936Phase 1
- Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic LeukemiaCompletedNCT02042911Phase 2
- Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell LymphomaCompletedNCT01718691Phase 2
- Study of SyB L-0501 to Treat Relapsed/Refractory Multiple MyelomaCompletedNCT01849848Phase 2
- Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)CompletedNCT01700140Phase 2
- Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01118845Phase 2
- Efficacy and Safety Study of SyB L-0501 for Patients With Multiple MyelomaTerminatedNCT01179490Phase 2
- Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell LymphomaCompletedNCT00612183Phase 2